Hangzhou Tigermed Consulting Co Ltd
Hangzhou Tigermed Consulting Co Ltd operates as a contract research organization (CRO) providing drug discovery and development services, generating revenue through fee-for-service arrangements in the pharmaceutical and biotechnology sectors.
Business. Hangzhou Tigermed Consulting Co Ltd (3347.HK) is an IT services and consulting firm headquartered in Hangzhou. The company operates within the Technology sector, specifically providing IT consulting and other services. It is listed on the Hong Kong Stock Exchange under the ticker 3347.HK. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
11 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
- Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
- Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
- Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Hangzhou Tigermed Consulting Co Ltd (3347.HK) is an IT services and consulting firm headquartered in Hangzhou. The company operates within the Technology sector, specifically providing IT consulting and other services. It is listed on the Hong Kong Stock Exchange under the ticker 3347.HK. Specific details regarding operating segments and geographic revenue mix are not available.
Hangzhou Tigermed Consulting Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.09 and a current ratio of 2.18, indicating strong short-term liquidity coverage. The company holds total assets of 28.36 billion CNY against total liabilities of 7.40 billion CNY, resulting in total equity of 20.96 billion CNY. Despite the strong balance sheet, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, suggesting that cash and equivalents are insufficient to cover the 1.82 billion CNY in long-term debt. Operating cash flow stands at 1.12 billion CNY, while free cash flow is 573.69 million CNY after capital expenditures of 214.37 million CNY.
Profitability metrics indicate a compressed return profile relative to the asset base. The company reports a return on equity (ROE) of 3.68% and a return on assets (ROA) of 2.72%. With a net income of 887.89 million CNY on revenue of 6.83 billion CNY, the net margin is approximately 13%. The valuation snapshot reflects a depressed market perception, with a price-to-earnings (P/E) ratio of 5.91 and a price-to-book (P/B) ratio of 0.22, implying the market values the company at a significant discount to its tangible book value. The EV/EBITDA multiple of 5.02 and EV/Revenue of 0.9 further underscore the low valuation multiple applied by investors.
- The company trades at a deep discount to book value (P/B 0.22) and earnings (P/E 5.91), suggesting significant market pessimism or a perceived decline in asset quality.
- Strong liquidity coverage is evident with a current ratio of 2.18, but net cash is negative after accounting for total debt, creating a medium liquidity risk flag.
- Profitability is modest with an ROE of 3.68% and ROA of 2.72%, indicating inefficient capital utilization relative to the equity base.
- Analyst sentiment is positive with a mean recommendation of 2.00 and a mean price target of 54.39 CNY, implying ~47% upside from the current price.
- Dilution risk is low, with no difference between basic and diluted share counts, and no recent equity issuance indicated.
Bull / Bear case
Generated · model-assistedAnalysts project 51.2% upside to a mean price target of 55.98, reflecting strong market confidence in the stock.
Net margin of 10.91% ranks above the 75th percentile of the IT Services cohort, demonstrating strong cost control.
Free cash flow surged 353% year-over-year to 573.7 million CNY, highlighting improved cash generation capabilities.
Debt-to-equity ratio of 0.09 is lower than the cohort median of 0.12, suggesting a conservative capital structure.
Net income CAGR of -25.5% over four years signals a severe long-term decline in profitability trends.
Revenue growth slowed to just 3.5% year-over-year, indicating stagnating top-line expansion in the latest period.
Return on equity of 3.68% falls below the IT Services cohort median of 4.17%, showing weaker capital efficiency.
Gross profit declined to 1.87 billion CNY in FY2026, down from 2.82 billion CNY in FY2024, eroding margins.
Medium liquidity risk flags potential challenges in meeting short-term obligations, warranting caution for investors.
In focus — financials by report
Revenue ¥1.80B, +15,2% YoY; Operating income +180,8% YoY.
- ▍Revenue ¥1.80B, +15,2% YoY
- ▍Operating income +180,8% YoY
- ▍Net income −70,4% YoY
- ▍Net margin 2.7%
Revenue ¥1.81B, +17,7% YoY; Operating income +47,8% YoY.
- ▍Revenue ¥1.81B, +17,7% YoY
- ▍Operating income +47,8% YoY
- ▍Net income +67,5% YoY
- ▍Net margin -7.3%
Revenue ¥1.78B, +3,9% YoY; Operating income +97,2% YoY.
- ▍Revenue ¥1.78B, +3,9% YoY
- ▍Operating income +97,2% YoY
- ▍Net income +98,7% YoY
- ▍Net margin 35.9%
Revenue ¥1.69B, −0,7% YoY; Operating income −7,7% YoY.
- ▍Revenue ¥1.69B, −0,7% YoY
- ▍Operating income −7,7% YoY
- ▍Net income −15,5% YoY
- ▍Net margin 12.9%
Revenue ¥1.56B; Operating income ¥144.5M.
- ▍Revenue ¥1.56B
- ▍Operating income ¥144.5M
- ▍Net margin 10.6%
Revenue ¥1.54B; Operating income -¥420.6M.
- ▍Revenue ¥1.54B
- ▍Operating income -¥420.6M
- ▍Net margin -26.6%
Revenue ¥1.71B; Operating income ¥397.9M.
- ▍Revenue ¥1.71B
- ▍Operating income ¥397.9M
- ▍Net margin 18.8%
Revenue ¥1.70B; Operating income ¥324.9M.
- ▍Revenue ¥1.70B
- ▍Operating income ¥324.9M
- ▍Net margin 15.2%
Revenue ¥6.83B, +3,5% YoY; Operating income +51,8% YoY.
- ▍Revenue ¥6.83B, +3,5% YoY
- ▍Operating income +51,8% YoY
- ▍Net income +119,2% YoY
- ▍Free cash flow +353,0% YoY
- ▍Net margin 13.0%
Revenue ¥6.60B, −10,6% YoY; Operating income −73,5% YoY.
- ▍Revenue ¥6.60B, −10,6% YoY
- ▍Operating income −73,5% YoY
- ▍Net income −80,0% YoY
- ▍Free cash flow −114,3% YoY
- ▍Net margin 6.1%
Revenue ¥7.38B, +4,2% YoY; Operating income −5,1% YoY.
- ▍Revenue ¥7.38B, +4,2% YoY
- ▍Operating income −5,1% YoY
- ▍Net income +0,5% YoY
- ▍Free cash flow −2,4% YoY
- ▍Net margin 27.4%
Revenue ¥7.09B, +35,9% YoY; Operating income −28,7% YoY.
- ▍Revenue ¥7.09B, +35,9% YoY
- ▍Operating income −28,7% YoY
- ▍Net income −30,0% YoY
- ▍Free cash flow −44,7% YoY
- ▍Net margin 28.5%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,01 |
| Revenue | —no estimate | —no estimate | 7,7B CNY |
| Operating income | —no estimate | —no estimate | 963,9M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Ev To Operating Incomeenterprise_value / operating_income
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Enterprise Valuemarket_cap - net_cash
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Capmarket_price * shares_outstanding_diluted
- Hangzhou Tigermed Consulting Co Ltd Market data — financials · 2026-07-06
- Hangzhou Tigermed Consulting Co Ltd Market data — analyst estimates · 2026-07-06
- Hangzhou Tigermed Consulting Co Ltd Market data — ESG · 2026-07-06
Ownership & reference
Leadership
- Xiaoping YeExecutive Chairman of the Board